The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 39 cents per share. The biotechnology company posted ...
News
- NGM Biopharmaceuticals: Q2 Earnings Snapshot
- Fate Therapeutics: Q2 Earnings Snapshot
The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of 52 cents per share. The clinical-stage biotech company ...
- Entrepreneurs Disrupt Wasteful Supply Chain Practices
This fact was simply unacceptable to the founders of Strella Biotech. They created technology to essentially “hack fruit.” With sensors, IoT networks and ...
- PETA asks feds to penalize San Antonio lab after 159 of its baboons suffered amputations from ...
Nearly 160 baboons in captivity at San Antonio's Texas Biomedical Research Institute (TBRI) suffered amputations due to frostbite from February's ...
- Lyme disease protection: No vaccine yet, but an antibody shot could soon provide a season of ...
Today, a French biotech company, in collaboration with Pfizer, is attempting to develop a Lyme vaccine; it is currently in clinical trials. A different ...